STAAR Reports 6 Percent Increase in Net Sales in Q1-2017

May 12, 2017: By Jon Swedien

STAARSTAAR Surgical had net sales of $20.4 million in Q1-2017, a 6 percent increase over its Q1-2016 net sales, the company reported May 3.

Net sales of STAAR’s Visian Implantable Collamer Lens (ICL) were up 16 percent for Q1-2017 compared with the same quarter in 2016, according to the Monrovia, California, company.

The number of ICLs units sold was up 20 percent for Q1-2017 compared with Q1-2016.

STAAR’s sales for ICLs grew 65 percent in Canada, 65 percent in Japan, and 45 percent in China in Q1-2017 compared with Q1-2016, the company said.

The company’s IOL sales were down 9 percent in Q1-2017 compared with Q1-2016, while the number of units sold was flat. Injector parts dropped 54 percent.

STAAR said it anticipates flat to declining growth for IOL sales in 2017 with the discontinuation of its US silicone IOL business.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

Sentencing Delayed for Florida Retina Specialist Melgen

Valeant Receives FDA Complete Response Letter for Vyzulta

US FDA Clears Optovue Software for Corneal Epithelial Thickness Mapping

Ocular Therapeutix Names Daniel Bollag as Regulatory Chief

Eylea Sales Continue to Increase; Lucentis Gains New Indications

RXi Pharmaceuticals Signs Common Stock Purchase Agreement for Up to $15 Million

Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

Omeros’ Omidria Revenues Grow 71 Percent

AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

Aerpio Shares Begin Trading on OTCQB Market

Aerie Reports FDA Concerns over Contract Manufacturer’s Plant

Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

Johnson & Johnson Vision to Acquire TearScience

Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

Ocular Therapeutix Eliminates 26 Positions; New CEO Takes Helm

Inotek Stops Development of Trabodenoson after Second Failed Study

Coming soon

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022